featured
Clinical Response to Upadacitinib and Risankizumab Is Associated With Reduced IBD Anti–TNF-α Inadequate Response Mechanisms
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Inflammatory Bowel Diseases
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The Clinical Response of Upadacitinib and Risankizumab Is Associated With Reduced Inflammatory Bowel Disease Anti-TNF-α Inadequate Response Mechanisms
Inflamm. Bowel Dis. 2023 May 02;29(5)771-782, J Wang, M Macoritto, H Guay, JW Davis, MC Levesque, X CaoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.